Title:
IMIDAZOLINONE DERIVATIVE AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/240379
Kind Code:
A1
Abstract:
Provided in the present invention are an imidazolinone derivative and the use thereof. The imidazolinone derivative is a compound having a structure as shown in the following formula (I) or (II) or a pharmaceutically acceptable salt, stereoisomer, tautomer, prodrug or solvate thereof. The compound of the present invention has a significant inhibitory activity against the RIP1 kinase and can be used for treating RIP1 kinase-associated diseases, especially various inflammatory diseases.
More Like This:
| JP2023508383 | Dihydro-cyclopenta-isoquinoline derivatives |
| WO/2005/112925 | ARYL SULFONAMIDES |
Inventors:
HE GUANGWEI (CN)
CHU ZHAOXING (CN)
XU QINLONG (CN)
LIN GAOFENG (CN)
LI FENG (CN)
MO JIAJIA (CN)
CHU ZHAOXING (CN)
XU QINLONG (CN)
LIN GAOFENG (CN)
LI FENG (CN)
MO JIAJIA (CN)
Application Number:
PCT/CN2022/098307
Publication Date:
December 21, 2023
Filing Date:
June 13, 2022
Export Citation:
Assignee:
NANJING INST OF PHARMACEUTICAL INDUSTRY CO LTD (CN)
HEFEI INST OF PHARMACEUTICAL INDUSTRY CO LTD (CN)
HEFEI AMVITE PHARMACEUTICAL CO LTD (CN)
HEFEI INST OF PHARMACEUTICAL INDUSTRY CO LTD (CN)
HEFEI AMVITE PHARMACEUTICAL CO LTD (CN)
International Classes:
C07D413/12; A61K31/553; A61P1/00; A61P1/02; A61P1/04; A61P1/16; A61P1/18; A61P3/00; A61P9/00; A61P9/10; A61P11/00; A61P11/06; A61P13/12; A61P17/00; A61P17/04; A61P17/06; A61P17/08; A61P19/02; A61P19/06; A61P19/08; A61P25/14; A61P25/16; A61P25/28; A61P27/02; A61P29/00; A61P31/04; A61P31/06; A61P31/16; A61P35/00; A61P35/02; A61P37/06; A61P37/08; A61P43/00
Foreign References:
| CN105121432A | 2015-12-02 | |||
| CN110642874A | 2020-01-03 | |||
| CN109134448A | 2019-01-04 | |||
| CN111269221A | 2020-06-12 | |||
| US20220009936A1 | 2022-01-13 | |||
| US20170266199A1 | 2017-09-21 |
Other References:
WANG ZHANMEI, JING YU, JIE HAO, MINGHUI WANG, HONG LIAO, JINXIN WANG: "Research Progress of Receptor-interacting Protein 1 and Its Inhibitors", PROGRESS IN PHARMACEUTICAL SCIENCES, CHINA PHARMACEUTICAL UNIVERSITY, CN, vol. 42, no. 12, 31 December 2018 (2018-12-31), CN , pages 945 - 951, XP055866191, ISSN: 1001-5094
Attorney, Agent or Firm:
HAIWEN & PARTNERS (CN)
Download PDF: